Background Metformin is the most widely prescribed drug to lower glucose and has a
definitive effect on the cardiovascular system. The goal of this systematic review and meta …

Metformin is the oldest and most commonly used first-line antidiabetic drug because of its
good clinical efficacy, high safety, low cost and easy access. At the same time, in recent …

Multitargeting compounds comprising activity on more than a single biological target have
gained remarkable relevance in drug discovery owing to the complexity of multifactorial …

Simple Summary Cardiovascular diseases (CVDs) are the leading causes of death
worldwide. Epicardial adipose tissue (EAT) is one of the most important risk factors for …

Type 2 diabetes mellitus (T2DM) is a worldwide major health burden and heart failure (HF)
is the most common cardiovascular (CV) complication in affected patients. Therefore …

The translation of cardioprotection from robust experimental evidence to beneficial clinical
outcome for patients suffering acute myocardial infarction or undergoing cardiovascular …

Cardiovascular diseases (CVDs) are serious public health issues and are responsible for
nearly one-third of global deaths. Mitochondrial dysfunction is accountable for the …

The term “cardiovascular diseases”(CVD) refers to various ailments that affect the heart and
blood vessels, including myocardial ischemia, congenital heart defects, heart failure …

Metformin can suppress gluconeogenesis and reduce blood sugar by activating adenosine
monophosphate-activated protein kinase (AMPK) and inducing small heterodimer partner …

Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for
treating type 2 diabetes. There had been a significant concern regarding the use of …